– USA, PA – Alliqua BioMedical, Inc. (Nasdaq:ALQA), today announced the appointment of Andrew Africk and Gary Restani to its Board of Directors. The Company also announced the departure of David Stefansky and Kenneth D. Pearson from its Board of Directors.
Mr. Africk recently formed Searay Capital LLC after 21 years successfully leading private equity and capital markets investments for Apollo Global Management LLC, a leading global alternative asset manager with assets under management exceeding US $150 billion. As a Senior Partner at the firm, Mr. Africk was responsible for Apollo’s investments in technology and communications. Mr. Africk currently serves on the Board of Overseers of the University of Pennsylvania School of Engineering, the UCLA Science Board, and is a Trustee of the Trinity School in New York City.
Mr. Restani currently serves as Vice Chairman on the Board of Directors for Spiracur Inc., a privately held medical device company focused on the development of innovative wound healing technologies. He recently transitioned from President & CEO of Spiracur Inc. and has more than 40 years of experience in the medical device industry. Prior to joining Spiracur Inc. in 2010, Mr. Restani held both executive and operating positions for global medical device companies including: President and COO of Hansen Medical, President of Convatec, division president at both Zimmer and Smith & Nephew. He attended Sir George Williams University and Loyola University and holds a certificate from Dartmouth College for completing the Tuck School of Business’, General Management Executive Program.
“We are excited to add these highly experienced individuals to our Board of Directors and expect Alliqua BioMedical to benefit from Andrew’s financial acumen and Gary’s extensive experience in the medical technology sector,” said David Johnson, Chief Executive Officer of Alliqua. “We are also grateful to Dave and Ken for their contributions to the Company during their tenure and wish them both well.”
About Alliqua BioMedical, Inc.
Alliqua BioMedical is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua BioMedical provides a suite of technological solutions to enhance the wound care practitioner’s ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua BioMedical currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua BioMedical can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua BioMedical’s electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua BioMedical to develop and custom manufacture a wide variety of hydrogels. Alliqua BioMedical’s hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
